Wearable Heart Patch Checks for Hidden Atrial Fibrillation After Stroke
Tests a wearable heart patch to detect atrial fibrillation in people with unexplained stroke.
Key facts
- Who runs it
- Asan Medical Center
- Where
- Seoul, South KoreaSee the site
- Trial code
- Registry title
- Atrial Fibrillation Detection Using MEMO Patch in Patients With Stroke of Unknown Cause
- Status
- Recruiting
- People taking part
- 100 people, planned
- Started
- 28 Jan 2026
- Expected to end
- 15 Feb 2029
- Type of study
- Interventional
- Treatments tested
- MEMO Patch M and MEMO Patch2
- Record updated
- 6 February 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who had a stroke with no clear cause (ESUS) and need heart rhythm monitoring. A wearable ECG patch checks for atrial fibrillation that was not found before.
- Age
- 19 years or older
- Sex
- All sexes can join.
- Disease stage
- Embolic stroke of undetermined source (ESUS), meaning a stroke whose cause was not found.
Main reasons for not taking part
- Already diagnosed with atrial fibrillation or atrial flutter
- A clearly identified cause of the stroke
- Known allergy to adhesives or hydrogels
- Cognitive vulnerability that makes it hard to understand the study and decide to join, in the investigator's judgment
- Any other reason the principal investigator sees a risk in taking part
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Participants may take part in this clinical study only if they meet all of the following criteria:
- Adults aged 19 years or older who voluntarily provide written informed consent to participate in the study
- Patients diagnosed with ESUS (Embolic Stroke of Undetermined Source)
- Patients who require in-hospital or out-of-hospital electrocardiographic (ECG) monitoring
Who cannot take part
- Individuals with a clearly identified cause of stroke
- Individuals known to have allergic reactions to adhesives or hydrogels
- Participants who meet any of the following criteria cannot be enrolled in this clinical study:
- Individuals already diagnosed with atrial fibrillation or atrial flutter
- Individuals who, in the investigator's judgment, have cognitive vulnerability that makes it difficult to understand the study information and voluntarily decide on participation
- Any other individuals whom the principal investigator considers to be at potential risk by participating in the study or otherwise unsuitable for participation
Where in South Korea
- Asan Medical CenterSeoul, South KoreaContact: Bum Joon Kim, MD, PhDTaking people
About the trial
What the trial wants to find out
The purpose of this study is to evaluate the efficacy and safety of a wearable device in detecting previously undiagnosed atrial fibrillation through non-invasive long-term monitoring using a wearable single-lead ECG patch (MEMO Patch M, MEMO Patch2) in 100 patients with Embolic Stroke of Undetermined Source (ESUS) who require atrial fibrillation screening. Participants who meet all inclusion and exclusion criteria and provide written informed consent will wear the MEMO Patch M and undergo in-hospital telemetry monitoring using MEMO Cue for a minimum of 12 hours and up to 8 days. During hospitalization, 24-hour Holter monitoring will also be conducted. Before discharge, the investigator will review these results to determine whether implantable loop recorder (ILR) implantation is necessary. At the time of discharge, participants will wear MEMO Patch2 for up to 14 days for the first ECG monitoring period. One month after discharge, the investigator will review the results of the first monitoring and initiate the second ECG monitoring with MEMO Patch2. Three months after discharge, the results of the second ECG monitoring will be reviewed, and participation in the clinical trial will be completed.
The group in the trial
- MEMO Patch Long-Term Monitoring(MEMO Patch M, MEMO Patch2)Treatment being tested
Participants in this arm will undergo long-term ECG monitoring using MEMO Patch M during hospitalization and MEMO Patch2 after discharge. 24-hour Holter monitoring will also be performed, and ILR implantation will be assessed before discharge.
Treatment: MEMO Patch M and MEMO Patch2
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Atrial Fibrillation Detection Using MEMO Patch in Patients With Stroke of Unknown Cause: A Single-Center, Prospective, Exploratory Trial to Validate the Efficacy and Safety of Noninvasive Long-Term Electrocardiographic Monitoring
- Plain-language title
- Wearable Heart Patch Checks for Hidden Atrial Fibrillation After StrokeGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 6 February 2026